All Stories

  1. Development of a genetic priority score to predict drug side effects using human genetic evidence

    Article • Nature Communications, September 2025, Springer Science + Business Media

    Joshua K. Park

  2. Genetic analyses of eight complex diseases using predicted continuous representations of disease

    Article • Cell Reports Methods, August 2025, Elsevier

    Joshua K. Park

  3. Evaluation of a machine learning-based metabolic marker for coronary artery disease in the UK Biobank

    Article • Atherosclerosis, February 2025, Elsevier

    Joshua K. Park

  4. Expanding drug targets for 112 chronic diseases using a machine learning-assisted genetic priority score

    Article • Nature Communications, October 2024, Springer Science + Business Media

    Joshua K. Park

  5. Exome sequence analysis identifies rare coding variants associated with a machine learning-based marker for coronary artery disease

    Article • Nature Genetics, June 2024, Springer Science + Business Media

    Joshua K. Park

  6. Genome-first evaluation with exome sequence and clinical data uncovers underdiagnosed genetic disorders in a large healthcare system

    Article • Cell Reports Medicine, May 2024, Elsevier

    Joshua K. Park

  7. Muesli Intake May Protect Against Coronary Artery Disease

    Article • JACC Advances, April 2024, Elsevier

    Joshua K. Park

  8. Development of a human genetics-guided priority score for 19,365 genes and 399 drug indications

    Article • Nature Genetics, January 2024, Springer Science + Business Media

    Joshua K. Park

  9. In vitro and in vivo pharmacokinetic characterization, chiral conversion and PBPK scaling towards human PK simulation of S-MRI-1867, a drug candidate for Hermansky-Pudlak syndrome pulmonary fibrosis

    Article • Biomedicine & Pharmacotherapy, December 2023, Elsevier

    Joshua K. Park

  10. Abstract P1179: Evaluation Of A Machine Learning-based Metabolic Marker For Coronary Artery Disease In The UK Biobank

    Article • Circulation Research, August 2023, Wolters Kluwer Health

    Joshua K. Park

  11. A machine learning model identifies patients in need of autoimmune disease testing using electronic health records

    Article • Nature Communications, April 2023, Springer Science + Business Media

    Joshua K. Park

  12. Machine Learning Identifies Plasma Metabolites Associated With Heart Failure in Underrepresented Populations With the TTR V122I Variant

    Article • Journal of the American Heart Association, April 2023, Wolters Kluwer Health

    Joshua K. Park

  13. An Integrative Multiomics Framework for Identification of Therapeutic Targets in Pulmonary Fibrosis

    Article • Advanced Science, April 2023, Wiley

    Joshua K. Park

  14. Phenome-wide Mendelian Randomization of Triglycerides and 2600 Diseases

    Article • eLife, March 2023, eLife

    Joshua K. Park

  15. Machine learning-based marker for coronary artery disease: derivation and validation in two longitudinal cohorts

    Article • The Lancet, January 2023, Elsevier

    Joshua K. Park

  16. Short-term prediction of coronary artery disease using serum metabolomic patterns

    Article • American Heart Journal Plus Cardiology Research and Practice, December 2022, Elsevier

    Joshua K. Park

  17. Phenome-wide Mendelian randomization study of plasma triglycerides and 2,600 disease traits

    Article • July 2022, openRxiv

    Joshua K. Park

  18. Peripheral Hybrid CB1R and iNOS Antagonist MRI-1867 Displays Anti-Fibrotic Efficacy in Bleomycin-Induced Skin Fibrosis

    Article • Frontiers in Endocrinology, September 2021, Frontiers

    Joshua K. Park

  19. CB 1 R and iNOS are distinct players promoting pulmonary fibrosis in Hermansky–Pudlak syndrome

    Article • Clinical and Translational Medicine, July 2021, Wiley

    Joshua K. Park

  20. The Heterogeneity of Lipid Metabolism in Cancer

    Article • January 2021, Springer Science + Business Media

    Joshua K. Park

  21. Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice

    Article • Nature Chemical Biology, May 2020, Springer Science + Business Media

    Dr Resat Cinar, Joshua K. Park

  22. Bleomycin Induces Drug Efflux in Lungs: A pitfall for Pharmacological Studies of Pulmonary Fibrosis

    Article • American Journal of Respiratory Cell and Molecular Biology, August 2019, American Thoracic Society

    Dr Resat Cinar, Joshua K. Park

  23. Targeting Peripheral CB1 Receptors Reduces Ethanol Intake via a Gut-Brain Axis

    Article • Cell Metabolism, June 2019, Elsevier

    Joshua K. Park

  24. The Heterogeneity of Lipid Metabolism in Cancer

    Article • January 2018, Springer Science + Business Media

    Joshua K. Park

  25. Cannabinoid-1 receptor deletion in podocytes mitigates both glomerular and tubular dysfunction in a mouse model of diabetic nephropathy

    Article • Diabetes Obesity and Metabolism, December 2017, Wiley

    Dr. Janos Paloczi, Joshua K. Park, Dr Resat Cinar

  26. Network analyses identify liver‐specific targets for treating liver diseases

    Article • Molecular Systems Biology, August 2017, EMBO

    Professor Adil Mardinoglu, Sunjae Lee, Tim Kuijpers, Joshua K. Park, Dr Resat Cinar, Professor Morten Grötli

  27. Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis

    Article • JCI Insight, April 2017, American Society for Clinical Investigation

    Joshua K. Park, Dr Resat Cinar

  28. Developmental Role of Macrophage Cannabinoid-1 Receptor Signaling in Type 2 Diabetes

    Article • Diabetes, January 2017, American Diabetes Association

    Joshua K. Park, Dr Resat Cinar

  29. Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer

    Article • Proceedings of the National Academy of Sciences, August 2016, Proceedings of the National Academy of Sciences

    Joshua K. Park

  30. Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis

    Article • JCI Insight, July 2016, American Society for Clinical Investigation

    Joshua K. Park

  31. Glucose-Independent Glutamine-Driven TCA Cycle in Cancer Cells

    Article • November 2014, Springer Science + Business Media

    Joshua K. Park

  32. Abstract 852: Novel role and mechanism of the LDHA protein as a survival factor for cancer cells.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Joshua K. Park